ArticleViruses2025
Differential Profile of Hemostasis in Dengue Fever Before and After COVID-19.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dengue and COVID-19 are viral diseases characterized by coagulopathies, with Dengue associated with fibrinolysis and COVID-19 with prothrombotic events. Furthermore, cross-reactivity between anti-SARS-CoV-2 and anti-DENV antibodies may confer protective immunity or exacerbate disease severity. Our investigation explored the impact of prior COVID-19 exposure on the immunopathogenesis of Dengue, focusing on hemostatic parameters. We quantified nitrites, procoagulant, anticoagulant, and fibrinolytic mediators in the plasma of Dengue patients before and after the COVID-19 pandemic. We also evaluated the influence of plasma from dengue patients on platelet activation in vitro using platelets from healthy donors exposed to DENV-2. Hemorrhagic manifestations were more frequent in pre-COVID-19 Dengue, while nitrite levels were elevated in post-COVID-19 Dengue patients, particularly among those without hemorrhagic signs. Among procoagulant factors, tissue factor (TF) levels were increased in post-COVID-19 Dengue, whereas Factor XIII was higher in pre-COVID-19 Dengue. In contrast, antithrombin (an anticoagulant) and plasminogen (a profibrinolytic factor) were more elevated in pre-COVID-19 Dengue than in post-COVID-19 cases. In vitro, DENV-2-infected platelets exposed to plasma of Dengue patients before and after COVID-19 showed decreased nitrite production in relation to DENV-2 alone. These findings suggest that prior COVID-19 exposure may influence hemostatic responses in Dengue, potentially modulating disease pathophysiology and opening new avenues for research and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.